Inhibition of HER2-mediated downstream signaling (basal phospho-Akt) by ABP 980, trastuzumab (US), and trastuzumab (EU) was evaluated in BT-474 human breast cancer cells (26). Here, AKT1 is linked to breast carcinoma.